We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Monkeypox, an emerging zoonotic disease caused by the monkeypox virus (MPXV), has garnered significant scientific attention due to its resemblance to smallpox and its potential for outbreaks. One of the key viral proteins, D8L, is a membrane glycoprotein critical for the virus's life cycle and immune evasion, making it an ideal target for research purposes. Creative Biolabs, a leading provider of custom antibody development services, offers cutting-edge solutions tailored to your D8L-related research needs.
Creative Biolabs specializes in providing end-to-end solutions for developing high-specificity antibodies targeting the D8L glycoprotein of MPXV. Our streamlined services are designed to meet your research needs efficiently:
Using cutting-edge bioinformatics and recombinant protein technologies, we design and produce highly immunogenic D8L antigens, optimized to elicit robust and specific immune responses for antibody development.
Our tailored immunization strategies involve multiple animal models, including mice, rats, and rabbits, ensuring the generation of high-affinity antibodies with specificity for D8L.
Leveraging proprietary phage display platforms and advanced hybridoma technology, we create diverse libraries and isolate monoclonal antibodies with exceptional binding properties targeting D8L.
To enhance the functionality of D8L antibodies, we provide services such as affinity maturation, humanization, and the development of bispecific or multispecific antibody formats, tailored to diverse research needs.
We ensure the reliability of our antibodies through rigorous validation processes, including epitope mapping of D8L, functional assays to test binding and neutralization, and structural studies using cryo-EM or X-ray crystallography.
The D8L glycoprotein plays a dual role in the life cycle of MPXV, making it a pivotal target for researchers:
D8L mediates the attachment of the virus to host cell membranes, enabling viral entry. This glycoprotein interacts with host cell surface receptors, overcoming initial immune defenses.
D8L is also implicated in evading host immune responses. By masking key viral epitopes, D8L helps MPXV avoid detection and clearance, ensuring the virus's survival and replication within host cells.
| Cat# | Product Name | Target | Antibody Isotype | Species Reactivity | Applications |
|---|---|---|---|---|---|
| MPYF-1022-KX1578 | Anti-Variola (Smallpox) Virus D8L Monoclonal Antibody (MP-K1512) (Mouse IgG) | D8L | Mouse IgG | Variola (Smallpox) Virus | WB (Other applications need to be tested) |
| MPYF-1022-KX1395 | Anti-Vaccinia Virus (Smallpox Vaccine) D8L Monoclonal Antibody (MP-K1329) (Mouse IgG) | D8L | Mouse IgG | Vaccinia Virus (Smallpox Vaccine) | WB (Other applications need to be tested) |
| MPYF-0822-YF17 | Anti-Vaccinia Virus D8L Monoclonal Antibody (MP-X17) (Mouse IgG2a, kappa) | D8L | Mouse IgG2a, kappa | Vaccinia Virus | Neut, ELISA |
| MPYF-0822-YF114 | Anti-Monkeypox Virus D8L Monoclonal Antibody (MP-W79) (Mouse IgG) | D8L | Mouse IgG | Monkeypox Virus | WB (Other applications need to be tested) |
| Cat# | Product Name | Species | Expression System | Target Protein | Protein Length |
|---|---|---|---|---|---|
| MPYF-0922-KX530 | Magic™ Vaccinia Virus (Smallpox Vaccine) (Western Reserve) D8L Recombinant Protein | Vaccinia Virus (Smallpox Vaccine) | Based on specific requirements | D8L | Full length |
| MPYF-0722-KX86 | Magic™ Vaccinia virus (Copenhagen) D8L Recombinant Protein Expressed in E. coli, 10xHis- | Vaccinia virus | E. coli | D8L | Full Length |
| MPYF-0722-KX57 | Magic™ Vaccinia virus (Copenhagen) D8L Recombinant Protein Expressed in E. coli, 6xHis-SUMO- | Vaccinia virus | E. coli | D8L | Full Length |
| MPYF-0922-KX713 | Magic™ Variola (Smallpox) Virus (India-1967, Ind5) D8L Recombinant Protein | Variola (Smallpox) Virus | Based on specific requirements | D8L | Full length |
| MPYF-0722-KX114 | Magic™ Monkeypox virus (Zaire-96-I-16) D8L Recombinant Protein | Monkeypox virus | Based on specific requirements | D8L | Full length |
| MPYF-0722-KX80 | Magic™ Vaccinia virus (Copenhagen) D8L Recombinant Protein Expressed in E. coli, 6xHis- | Vaccinia virus | E. coli | D8L | Full Length |
| Cat# | Product Name | Species | Target |
|---|---|---|---|
| MPYF-0722-KX1507 | Monkeypox virus, D8L-R | Monkeypox virus | D8L |
| MPYF-0722-KX1316 | Monkeypox virus, D8L-F | Monkeypox virus | D8L |
| Cat# | Product Name | Species | Target |
|---|---|---|---|
| MPYF-0722-KX1125 | Magic™ Monkeypox virus D8L Expression Plasmid | Monkeypox virus | D8L |
Creative Biolabs employs advanced platforms to support D8L antibody development, including:
For the discovery of antibodies with exceptional specificity.
For generating stable monoclonal antibodies.
Ensuring the high-quality generation of D8L antigens.
For the rapid selection of optimal candidates.
D8L-specific antibodies have a wide range of applications, including:
Creative Biolabs is committed to excellence and innovation. Choosing us ensures:
D8L is critical for MPXV's viral entry and immune evasion, making it an ideal target for understanding viral mechanisms and developing diagnostic tools.
Creative Biolabs can generate monoclonal, polyclonal, humanized, bispecific, and recombinant antibodies tailored to your needs.
Creative Biolabs provides antibodies in formats including IgG, scFv, and Fab, as well as custom conjugates.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.